How are Death Receptors Targeted in Drug Development?
Death receptors are a focus of drug development efforts aimed at modulating apoptosis. Agonistic antibodies and recombinant ligands are being explored to activate death receptors selectively in cancer cells, inducing apoptosis and inhibiting tumor growth. Additionally, small molecule inhibitors that block the interaction between death receptors and their ligands are being developed to treat conditions where excessive apoptosis is detrimental, such as neurodegenerative diseases.
